Erythromycin versus neomycin in the treatment of hepatic encephalopathy in cirrhosis: A randomized double-blind study

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Romeiro, Fernando Gomes ^a   da Silva Yamashiro, Fabio ^a   Américo, Madileine Francely ^b   Corá, Luciana Aparecida ^c   Silva, Giovanni Faria ^a   Miranda, JoséRicardodeArruda ^a   Caramori, Carlos Antonio ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b Universidade Federal do Mato Grosso/UFMT   (Brazil)

^c UNIVERSIDADE ESTADUAL DE CIÊNCIAS DA SAÚDE DE ALAGOAS   (Brazil)

Author keywords

Erythromycin; Hepatic encephalopathy; Liver cirrhosis; Neomycin

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; C REACTIVE PROTEIN; ERYTHROMYCIN; ERYTHROMYCIN ESTOLATE; NEOMYCIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL EXAMINATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEPATIC ENCEPHALOPATHY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KIDNEY EXAMINATION; LENGTH OF STAY; LIVER CIRRHOSIS; LIVER EXAMINATION; MALE; NEUROPSYCHOLOGICAL TEST; PRESCRIPTION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; AGED; ALANINE TRANSAMINASE; ANTI-BACTERIAL AGENTS; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ERYTHROMYCIN; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; LENGTH OF STAY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NEOMYCIN; TREATMENT OUTCOME;

EID: 84872204045     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-13     Document Type: Article

References (34)

1. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25:3-9.
2. Al Sibae MR, McGuire BM. Current trends in the treatment of hepatic encephalopathy. Ther Clin Risk Manag 2009, 5:617-626. 2724191, 19707277.
3. Moriwaki H, Shiraki M, Iwasa J, Terakura Y. Hepatic encephalopathy as a complication of liver cirrhosis: An Asian perspective. J Gastroenterol Hepatol 2010, 25:858-863.
4. Wijdicks EFM, Wiesner RH. Acquired (Non-Wilsonian) hepatocerebral degeneration: complex management decisions. Liver Transplantation 2003, 9(9):993-994. 10.1053/jlts.2003.50107, 12942464.
5. Cardenas A, Ginès P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 2005, 42:S124-S133. 10.1016/j.jhep.2004.12.007, 15777567.
6. Bass N. Review article: the current pharmacological therapies for hepatic encephalopathy. Aliment Pharmacol Ther 2006, 25(Suppl):23-31.
7. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004, 328:1046. 10.1136/bmj.38048.506134.EE, 403844, 15054035.
8. Lakshmi CP, Ghoshal UC, Kumar S, Goel A, Misra A, Mohindra S, et al. Frequency and factors associated with small intestinal bacterial overgrowth in patients with cirrhosis of the liver and extra hepatic portal venous obstruction. Dig Dis Sci 2010, 55:1142-1148. 10.1007/s10620-009-0826-0, 19424796.
9. Pande C, Kumar A, Sarin SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther 2009, 29:1273-1281. 10.1111/j.1365-2036.2009.03994.x, 19302262.
10. Madrid AM, Hurtado C, Venegas M, Cumsille F, Defilippi C. Long-Term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol 2001, 96:1251-1255. 10.1111/j.1572-0241.2001.03636.x, 11316178.
11. Park CH, Joo YE, Kim HS, Choi SK, Rew JS, Kim SJ. Neostigmine for the treatment of acute hepatic encephalopathy with acute intestinal pseudo-obstruction in a cirrhotic patient. J Korean Med Sci 2005, 20:150-152. 10.3346/jkms.2005.20.1.150, 2808564, 15716622.
12. Gunnarsdottir SA, Sadik R, Shev S, Simrén M, Sjövall H, Stotzer PO, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol 2003, 98:1362-1370. 10.1111/j.1572-0241.2003.07475.x, 12818282.
13. Sugarbacker SP, Revhaug A, Wilmore DW. The Role of the Small Intestine in Ammonia Production after Gastric Blood Administration. Ann Surg 1987, 206:5-17. 10.1097/00000658-198707000-00002, 1492937, 3496861.
14. Croteau D, Bergeron MG, Lebel M. Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography. Aliment Pharmacol Ther 2001, 15:595-603. 10.1046/j.1365-2036.2001.00964.x, 11328252.
15. Potthast H, Schug B, Elze M, Schwerdtle R, Blume H. Comparison of the bioavailabilities of erythromycin estolate and erythromycin ethylsuccinate dry suspension preparations in steady state. Pharmazie 1995, 50:56-60.
16. Henry J, Turner P, Garland M, Esmieu F. Plasma and salivary concentrations of erythromycin after administration of three different formulations. Postgrad Med J 1980, 56:707-710. 10.1136/pgmj.56.660.707, 2426034, 7220406.
17. Barré J, Mallat A, Rosenbaum J, Deforger L, Houin G, Dhumeaux D, et al. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity. Br J Clin Pharmacol 1987, 23:753-757. 10.1111/j.1365-2125.1987.tb03111.x, 1386171, 3606934.
18. Deane A, Chapman MJ, Fraser RJ, Bryant LK, Burgstad C, Nguyen NQ, et al. Mechanisms underlying feed intolerance in the critically ill: Implications for treatment. World J Gastroenterol 2007, 13:3909-3917.
19. Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005, 46:399-407. 10.3349/ymj.2005.46.3.399, 2815818, 15988813.
20. Edwin N, Peter JV, John G, Eapen CE, Graham PL. Relationship between clock and star drawing and the degree of hepatic encephalopathy. Postgrad Med J 2011, 87:605-611. 10.1136/pgmj.2010.108985, 21693571.
21. Morgan MY, Blei A, Grüngreiff K, Jalan R, Kircheis G, Marchesini G, et al. The treatment of hepatic encephalopathy. Metab Brain Dis 2007, 22:389-405. 10.1007/s11011-007-9060-7, 17846875.
22. Strauss E, da Costa MF. The importance of bacterial infections as precipating factors of chronic hepatic encephalopathy in cirrhosis. Hepatogastroenterology 1998, 45:900-904.
23. Bajaj JS, Riggio O. Drug therapy: Rifaximin. Hepatology 2010, 52:1484-1488. 10.1002/hep.23866, 20814894.
24. Papadopoulus N, Soultati A, Goritsas C, Lazaropoulou C, Achimastos A, Adamopouloos A, et al. Nitric oxide, ammonia, and CRP levels in cirrhotic patients with hepatic encephalopathy. Is there a connection?. J Clin Gastrtoenterol 2010, 44:713-719.
25. Ferenci P, Lockwood A, Mullen K, et al. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 2002, 35(3):716-721. 10.1053/jhep.2002.31250, 11870389.
26. Gundling F, Seidl H, Schmidt T, Schepp W. Blood ammonia level in liver cirrhosis: a conditio sine qua non to confirm hepatic encephalopathy?. Eur J Gastroenterol Hepatol 2008, 20(3):246-247. 10.1097/MEG.0b013e3282f1d00c, 18301310.
27. Shawcross D, Jalan R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci 2005, 62:2295-2304. 10.1007/s00018-005-5089-0, 16158192.
28. Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: Role of inflammation and oxidative stress. World J Gastroenterol 2010, 16:3347-3357. 10.3748/wjg.v16.i27.3347, 2904880, 20632436.
29. Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010, 7:515-525. 10.1038/nrgastro.2010.116, 20703237.
30. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovia J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39:1441-1449. 10.1002/hep.20194, 15122774.
31. Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010, 53:849-855. 10.1016/j.jhep.2010.05.017, 20675008.
32. Nolan JP. The role of endotoxin in liver injury. Gastroenterology 1975, 69:1346-1356.
33. Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 2010, 52:1829-1835. 10.1002/hep.23917, 20890945.
34. Chen SJ, Wang LJ, Zhu Q, Cai JT, Chen T, Si JM. Effect of H pylori infection and its eradication on hyperammo-nemia and hepatic encephalopathy in cirrhotic patients. World J Gastroenterol 2008, 14(12):1914-1918. 10.3748/wjg.14.1914, 2700403, 18350632.